Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Pain Palliat Care Pharmacother ; 37(4): 321-323, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37791819

ABSTRACT

Tramadol is a commonly utilized analgesic in the United States. One common misconception is that tramadol is safer than other opioid medications, or less likely to cause physical dependence. Given these misconceptions, the likelihood of patients experiencing withdrawal after discontinuation may be commonly overlooked as well. A 68-year old female patient with fibromyalgia was referred to a clinical pharmacy pain clinic for medication management. The patient was evaluated one month after abrupt discontinuation of tramadol 50 mg every 6 h for at least 10 years of use. She reports concerning symptoms of significant mucus production, fullness in chest and soreness in neck. Although tramadol is a Schedule IV Controlled Substance the risk of physical dependence and likelihood of patients experiencing withdrawal symptoms after abrupt cessation should not be diminished. Tramadol should not be considered a "safer" opioid therapy without potential of classic or atypical withdrawal symptoms, as well as risk of abuse, misuse or addiction.


Subject(s)
Opioid-Related Disorders , Substance Withdrawal Syndrome , Tramadol , Female , Humans , United States , Aged , Tramadol/adverse effects , Analgesics, Opioid/adverse effects , Opioid-Related Disorders/drug therapy , Substance Withdrawal Syndrome/etiology , Substance Withdrawal Syndrome/diagnosis , Substance Withdrawal Syndrome/drug therapy , Pain/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...